[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Terra RM, Teixeira LR, Beyruti R, Takagaki TY, Vargas FS, Jatene FB: [Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital]. J Bras Pneumol; 2008 Jan;34(1):13-20
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].
  • [Transliterated title] Mesotelioma pleural maligno: experiência multidisciplinar em hospital público terciário.
  • OBJECTIVE: To evaluate the experience in diagnosing and treating malignant pleural mesothelioma (MPM) accumulated over 5 years in a tertiary public hospital.
  • The biopsy specimens for histopathological examination were obtained through thoracoscopy in 9 patients (53%), Cope needle in 5 (29.5%), and open pleural biopsy in 3 (17.5%).
  • The following histological types were identified: epithelial, in 14 patients (82%); sarcomatoid, in 1 (6%); and biphasic, in 2 (12%).
  • The therapeutic approaches used were as follows: multimodal (pleuropneumonectomy and adjuvant radiotherapy and chemotherapy) in 6 patients (35%); chemotherapy and radiotherapy in 6 (35%); radiotherapy alone in 3 (17.5%); and chemotherapy alone in 2 (12%).
  • CONCLUSIONS: In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature.
  • [MeSH-major] Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Brazil / epidemiology. Chemotherapy, Adjuvant. Delivery of Health Care, Integrated. Female. Hospitals, Public. Humans. Male. Middle Aged. Patient Care Team. Pneumonectomy / methods. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278371.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Tanzi S, Tiseo M, Internullo E, Cacciani G, Capra R, Carbognani P, Rusca M, Rindi G, Ardizzoni A: Localized malignant pleural mesothelioma: report of two cases. J Thorac Oncol; 2009 Aug;4(8):1038-40
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant pleural mesothelioma: report of two cases.
  • Localized malignant pleural mesothelioma is very rare tumor disease.
  • There are sporadic reports in the literature showing that this entity has a different biologic behavior compared with diffuse pleural mesothelioma.
  • We report two cases of radically resected localized pleural malignant mesothelioma, with a previous history of asbestos exposure.
  • Both cases showed a microscopic and immunohistochemical findings of malignant mesothelioma, biphasic and sarcomatoid lympho-histiocitoid variant type, respectively, without evidence of diffuse pleural spread.
  • The first is very peculiar case of bilateral localized malignant pleural mesothelioma with complete response to chemotherapy and localized late recurrence, radically resected and treated with adjuvant radiotherapy.
  • Both cases demonstrate that the localized malignant mesothelioma should be distinguished from diffuse form and that complete resection is associated with good prognosis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633479.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 May;3(5):499-504
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality treatment of malignant pleural mesothelioma.
  • INTRODUCTION: Multimodality treatment has achieved significant success in local control and treatment of early-stage malignant pleural mesothelioma patients.
  • METHODS: We have instituted a trimodality treatment protocol consisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy) hemithoracic irradiation, and platin-based chemotherapy in a multi-institutional setting.
  • Preoperative pulmonary function tests, echocardiogram, chest computed tomography, and magnetic resonance imaging scans were performed in all patients.
  • Histology was epithelial in 17, mixed in 2, and sarcomatoid in 1.
  • Twelve patients completed all three treatments.
  • CONCLUSIONS: Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449002.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Jänne PA, Taffaro ML, Salgia R, Johnson BE: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res; 2002 Sep 15;62(18):5242-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is a rare malignancy with no known curative modality.
  • We have determined the effects of EGFR inhibition in MPM cell lines in vitro, using four MPM cell lines derived from previously untreated patients with epithelial (H2461 and H2591), sarcomatoid (H2373), and biphasic (MSTO-211H) MPM.
  • Furthermore, treatment with ZD1839 led to a significant dose-dependent reduction of colony formation (41-89% at 10 microM) when MPM cells were grown in soft agarose.
  • Our findings demonstrate that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD1839 may be an effective therapeutic option for patients with MPM.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Epidermal Growth Factor / pharmacology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Phosphorylation. Signal Transduction / drug effects. Signal Transduction / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234991.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


5. Togashi K, Hosaka Y, Sato K: [Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia]. Kyobu Geka; 2007 Jan;60(1):49-52
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomatoid pleural mesothelioma presenting as posterior mediastinal tumor with dysphagia].
  • The tumor was resected, then postoperative radiotherapy (60Gy) and chemotherapy were performed.
  • Results of histological and immunohistochemical study showed that the tumor consisted of sarcomatoid mesothelioma.
  • Case 2: A 76-year-old man with dysphagia, chest pain and cough admitted to our department Radiological studies demonstrated a solid mass with a maximal diameter of 12cm in the posterior mediastinum. accompanied by abundant effusion in the bilateral pleural cavities.
  • The patient underwent open biopsy and histological and immunohistochemical study showed that the tumor consisted of sarcomatoid mesothelioma.
  • We report extremely rare cases of sarcomatoid mesothelioma that appeared to be posterior mediastinal tumor before surgery, and discuss the difficulty of diagnosing sarcomatoid mesothelioma with atypical clinical manifestations.
  • [MeSH-major] Deglutition Disorders / complications. Mediastinal Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249539.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol; 2006 May;1(4):289-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
  • INTRODUCTION: Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease.
  • We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival.
  • Induction therapy was four cycles of gemcitabine and cisplatin.
  • Patients without disease progression by computed tomography underwent EPP followed by adjuvant hemithoracic RT (54 cGy).
  • Histology was epithelioid in 14 patients and mixed or sarcomatoid five patients.
  • Nineteen patients received induction chemotherapy.
  • Response to induction therapy was complete in zero patients, partial in five patients, stable disease in six patients, and progression of disease in eight patients.
  • CONCLUSION: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409872.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW, Fong Y: Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther; 2006 Jan;5(1):48-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
  • BACKGROUND: NV1066, a replication-competent oncolytic herpes simplex virus type 1 (HSV-1) attenuated by a deletion in the gene gamma(1)34.5, preferentially replicates in and kills malignant cells. gamma(1)34.5 encodes ICP34.5, a viral protein essential for productive replication, which has homology with mammalian stress response induced GADD34 (growth arrest and DNA damage-inducible protein).
  • METHODS: Ten human malignant pleural mesothelioma (MPM) cell lines were infected with NV1066 at multiplicities of infection (MOI; ratio of viral particles per tumor cell) 0.005 to 0.8 in vitro, with and without cisplatin (1 to 4 microM).
  • RESULTS: Combination therapy with NV1066 and cisplatin showed strong synergism in epithelioid (H-2452, H-Meso), sarcomatoid (H-2373, H-28), and biphasic (JMN, Meso-9, MSTO-211H) MPM cell lines, and an additive effect in others.
  • In VAMT cells combination therapy enhanced viral replication 4 to 11-fold (p < 0.01) and cell kill 2 to 3-fold (p < 0.01).
  • Significant dose reductions for both agents (2 to 600-fold) were achieved over a wide range of therapeutic-effect levels (LD50-LD99) without compromising cell kill.
  • This provides a cellular basis for combination therapy with cisplatin and NV1066 to treat MPM and achieve synergistic efficacy, while minimizing dosage and toxicity.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 May 23;272(21):13731-7 [9153226.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2055-8 [10232586.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S71-4 [15950805.001]
  • [Cites] J Urol. 2005 Aug;174(2):741-6 [16006968.001]
  • [Cites] Hum Gene Ther. 1999 Dec 10;10(18):3013-29 [10609661.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):162-9 [10933051.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3342-53 [10955822.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1213-23 [12133274.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):337-42; discussion 342-3 [12192320.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):502-12; discussion 512-3 [12368679.001]
  • [Cites] Cancer Gene Ther. 2002 Nov;9(11):935-45 [12386832.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):967-78 [12522436.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1663-82 [14534679.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3225-32 [15131064.001]
  • [Cites] FASEB J. 2004 Jun;18(9):1001-3 [15059970.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4509-16 [15240543.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S103-19 [15261443.001]
  • [Cites] Eur J Biochem. 1981 Mar 16;115(1):207-16 [7227366.001]
  • [Cites] J Occup Med. 1983 May;25(5):409-25 [6854431.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Cancer Treat Rep. 1985 Jun;69(6):711-2 [4040424.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Antimicrob Chemother. 1987 Jun;19(6):815-22 [3610908.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(5):319-30 [1914074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3266-70 [1314384.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1156-63 [8201377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5247-51 [8202476.001]
  • [Cites] Ann Oncol. 1994 Apr;5(4):373-4 [8075038.001]
  • [Cites] J Virol. 1996 Jan;70(1):84-90 [8523596.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):466-71 [9012475.001]
  • [CommentIn] Cancer Biol Ther. 2006 Feb;5(2):238-9 [16552173.001]
  • [CommentIn] Cancer Biol Ther. 2006 Feb;5(2):236-7 [16481733.001]
  • (PMID = 16294031.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075416; United States / NCI NIH HHS / CA / R01 CA080982; United States / NCI NIH HHS / CA / R01 CA 76416; United States / NCI NIH HHS / CA / R01 CA/DK80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Cell Cycle Proteins; 0 / RNA, Small Interfering; 0 / Viral Proteins; EC 3.1.3.16 / PPP1R15A protein, human; EC 3.1.3.16 / Protein Phosphatase 1; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS7204; NLM/ PMC1383726
  •  go-up   go-down


8. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ: Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg; 2010 Aug;140(2):352-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
  • OBJECTIVE: Optimizing the multimodality treatment of malignant pleural mesothelioma depends on many factors including an adequate chemotherapeutic response.
  • Currently, chemotherapy regimens for patients with mesothelioma are empirically selected.
  • In vitro chemotherapy resistance in human mesothelioma has not been reported.
  • Our goal was to determine the prevalence of drug resistance in a large sample of malignant pleural mesothelioma using a commercially available assay.
  • METHODS: Tumors specimens (n = 203) were cultured for analysis of chemoresistance using the extreme drug resistance assay.
  • Each specimen was tested with 3 drugs: cisplatin, gemcitabine, and vinorelbine.
  • Drug resistance was characterized as low, intermediate, or extreme.
  • Forty-four (26%) patients received neoadjuvant chemotherapy before sampling and testing.
  • The distribution of histopathologic cell types was epithelial (103; 61%), mixed (57; 34%), and sarcomatoid (8; 5%).
  • RESULTS: A significant proportion of tumors had extreme/intermediate drug resistance to cisplatin (27%), gemcitabine (31%), or vinorelbine (59%).
  • Nineteen tumors (11%) had extreme/intermediate resistance to all 3 drugs.
  • No significant differences in chemoresistance were found in tumors of patients who had received neoadjuvant chemotherapy compared with those who had not.
  • CONCLUSIONS: The feasibility of performing off-site in vitro drug resistance assays on resected malignant mesothelioma specimens is reported.
  • A significant proportion of mesothelioma tumors exhibited extreme/intermediate resistance to cisplatin, gemcitabine, or vinorelbine.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Cisplatin / pharmacology. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Feasibility Studies. Humans. Middle Aged. Neoadjuvant Therapy. Patient Selection. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653100.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Pala C, Paliogiannis P, Serventi F, Trignano E, Trignano M: Multimodality approach to malignant pleural mesothelioma. A case report. Ann Ital Chir; 2010 Jan-Feb;81(1):37-40
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality approach to malignant pleural mesothelioma. A case report.
  • INTRODUCTION: We report a case of diffuse malignant pleural mesothelioma (DMPM) in a 68-years-old male patient who was admitted for right sited pleural effusion.
  • The patient was treated by multimodality approach consisting in surgical treatment with Extrapleural Pleuropneumonectomy followed by chemotherapy with Cisplatin and Pemetrexed.
  • CASE REPORT: The patient was admitted to our Institute for a right sited pleural effusion diagnosed on chest X ray.
  • Several grey nodular lesions involving the costal, diaphragmatic and mediastinic parietal pleural sheets were found.
  • Histological examination of the specimens extracted revealed the presence of epithelial malignant pleural mesothelioma with sarcomatoid areas.
  • Extrapleural pleuropneumonectomy was performed followed by a chemiotherapic treatment with Cisplatin and Pemetrexed.
  • DISCUSSION: Single treatments do not demonstrate an acceptable efficacy on the treatment of DMPM.
  • Multimodality therapy provides good survival improvement and acceptable quality of life for the patients.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593749.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Inomata M, Kawagishi Y, Yamada T, Miwa T, Hayashi R, Kashii T, Matsui S, Fukuoka J, Tobe K: [Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma].
  • We report 2 cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma.
  • We diagnosed pulmonary sarcomatoid carcinoma and started chemotherapy with carboplatin and paclitaxel, but it was ineffective.
  • We diagnosed pulmonary sarcomatoid carcinoma and started chemotherapy with carboplatin and paclitaxel.
  • The pulmonary sarcomatoid carcinoma was reported to have spred to the pleural and chest wall.
  • The present two cases showed prominent chest wall and pleural tumors with obscure primary lung tumors.
  • Therefore, we needed to differentiate sarcomatoid carcinoma from malignant pleural mesothelioma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163019.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


11. Katsuragi N, Shiraishi Y, Kita H, Toishi M, Miyasaka Y, Tanaka S: [Diffuse malignant pleural mesothelioma]. Kyobu Geka; 2007 Jan;60(1):35-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse malignant pleural mesothelioma].
  • Malignant pleural mesothelioma is an uncommon neoplasm that caused 647 deaths in Japan in 2004.
  • We reviewed the clinical features in 11 consecutive patients with pathologically confirmed diffuse malignant pleural mesothelioma in our institution from January 1997 to December 2002.
  • A definitive diagnosis was made by closed pleural biopsy in 8 patients, pleural fluid cytology in 2, and autopsy in 1.
  • Histological subtypes included epithelioid in 6 patients, sarcomatoid in 2, biphasic in 1, and unknown in 2.
  • International Mesothelioma Interest Group (IMIG) staging included stage II in 6 patients, stage III in 3, and stage IV in 2.
  • Treatment included intrapleural chemotherapy in 4 patients, extrapleural pneumonectomy in 3, pleural drainage in 2, and best supportive care in 2.
  • Median survival time after diagnosis was 3 (range, 0 to 51) months.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249536.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Uramoto H, Shimokawa H, Baba T, Shigematsu Y, Nagata Y, Ono K, Takenoyama M, Hanagiri T: [Experience in treating patients with malignant pleural mesothelioma]. J UOEH; 2010 Sep 1;32(3):257-64
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience in treating patients with malignant pleural mesothelioma].
  • The objective of this study was to analyze the outcome of patients with malignant pleural mesothelioma who were treated from 1993 to 2009.
  • We analyzed a total of 28 patients with malignant pleural mesothelioma.
  • Twelve and 16 of the patients underwent an extrapleural pneumonectomy and a pleural biopsy, respectively.
  • The histological types included 14 epithelial type, 8 biphasic type, and 6 sarcomatoid type.
  • Fourteen and eight of the patients underwent systemic chemotherapy and radiotherapy, respectively.
  • The 2-year survival rate of all the patients was 25.7%, and the 2-year survival of the patients with at least one more modalities of the treatments with chemotherapy, radiotherapy and extrapleural pneumonectomy were much higher than those without.
  • We should therefore consider selecting a multimodality treatment for such patients because the administration of either systemic chemotherapy or radiotherapy was found to be associated with a favorable prognosis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pneumonectomy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20857819.001).
  • [ISSN] 0387-821X
  • [Journal-full-title] Journal of UOEH
  • [ISO-abbreviation] J. UOEH
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Zielinski M, Hauer J, Hauer L, Pankowski J, Nabialek T, Szlubowski A: Staging algorithm for diffuse malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):185-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging algorithm for diffuse malignant pleural mesothelioma.
  • An algorithm of preoperative mediastinal nodal staging with endobronchial/endoesophageal ultrasonography (EBUS/EUS) and transcervical extended mediastinal lymphadenectomy (TEMLA) combined with laparoscopy/peritoneal lavage and cytology was analyzed to establish the realistic criteria for radical multimodality treatment of malignant pleural mesothelioma (MPM).
  • The algorithm included computed tomography (CT), thoracoscopy with multiple pleural biopsies and talc pleurodesis, EBUS/EUS and one-stage TEMLA and laparoscopy/peritoneal lavage and cytology of the fluid.
  • There were 16 women and 26 men in ages ranging from 43 to 77 years (mean 57.8); 31 epithelioid, 2 sarcomatoid and 9 biphasic type MPM.
  • 21/42 patients were considered possible candidates for multimodality treatment.
  • Three patients who received neoadjuvant chemotherapy were excluded from this study.
  • [MeSH-major] Algorithms. Mesothelioma / diagnosis. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy. Chemotherapy, Adjuvant. Endosonography. Female. Humans. Laparoscopy. Lymph Node Excision. Lymphatic Metastasis. Male. Medical Futility. Middle Aged. Patient Selection. Peritoneal Lavage. Pleurodesis. Predictive Value of Tests. Radiotherapy, Adjuvant. Thoracoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843550.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • The subcutis is a particularly rare site of metastatic sarcomatoid mesothelioma.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


15. Okubo K, Sonobe M, Fujinaga T, Shoji T, Sakai H, Miyahara R, Bando T, Date H, Shibuya K, Hiraoka M: Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg; 2009 Nov;57(11):585-90
Kyoto University Research Information Repository - Articles. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
  • PURPOSE: Multimodality therapy has been applied to resectable malignant pleural mesothelioma, but the tolerability of the treatment and relapse pattern in detail remain unknown.
  • We reviewed our experience of trimodality therapy as a single-institution study in Japan.
  • METHODS: A total of 16 patients with resectable malignant pleural mesothelioma were intended to treat with extra-pleural pneumonectomy followed by platinum-based chemotherapy and external beam radiation therapy.
  • The histology of the tumors was epithelioid in 10, sarcomatoid in 4, and biphasic in 2.
  • International Mesothelioma Interest Group staging was stage II in 1, stage III in 11, and stage IV in 4.
  • The tolerability to the combined treatment, the survival, and the relapse pattern were examined.
  • In all, 14 patients received chemotherapy, and subsequently 13 underwent radiotherapy, indicating a tolerability of 81%.
  • CONCLUSION: Trimodality therapy showed a survival benefit in patients with stage III or lower malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local. Neoplasms, Mesothelial / therapy. Pleural Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiation Dosage. Radiotherapy, Adjuvant / adverse effects. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):346-50 [11251277.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Aug;22(2):298-305 [12142203.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Eur J Respir Dis. 1984 Apr;65(3):162-8 [6202538.001]
  • [Cites] Cancer J. 2003 Nov-Dec;9(6):476-84 [14740977.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):245-52 [15223437.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):334-8 [9033296.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1587-92 [17892915.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):382S-384S [8462330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-75 [12573764.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):491-6 [12189542.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 19908112.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Janne PA, Obasaju C, Simon G, Taub R, Kelly K, Fidias P, Bloss LP, Kindler HL: A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).
  • Treatment consisted of gemcitabine 1250 mg/m2 on days 1 and 8, with pemetrexed 500mg/m2 on day 8, followed by gemcitabine, every 21 days for a total of 6 cycles or until progressive disease.
  • Pathologic diagnosis included epithelial 68.3%, mixed 12.2%, sarcomatoid 7.3%, and unclassified/other 12.2%.
  • Early response data is promising and time-to-event, updated response, and survival information on all 53 patients will be forthcoming.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Flores RM, Krug L, Rosenzweig KE, Vincent A, Akhurst T, Heelan R, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7193

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM).
  • : 7193 Background: Approximately 25% of patients (pts) with malignant pleural mesothelioma (MPM) prove unresectable at surgery and the median survival of stage III MPM is <12 months even after complete resection by extrapleural pneumonectomy (EPP).
  • Improving chemotherapy for MPM led us to test induction chemotherapy followed by EPP and adjuvant hemithoracic radiation (RT) for locally advanced MPM to assess feasibility and estimate survival.
  • Induction therapy was: gemcitabine (1250mg/m<sup>2</sup>days 1, 8) and cisplatin (75mg/m<sup>2</sup>day 8) x 2-4 cycles.
  • Pts underwent EPP 3-5 weeks after induction therapy, then 54 Gy RT 4-6 weeks postop.
  • Chemotherapy response was assessed by RECIST criteria.
  • RESULTS: 21 pts (15 men, median age = 60 years) were consented to study, 19 received chemotherapy.
  • MPM histology was epithelial = 14, mixed or sarcomatoid =5.
  • 10 pts completed 4 chemotherapy cycles, while 9 received 1-2 cycles.
  • This experience supports additional studies of induction and multimodality therapy, especially with regimens such as cisplatin and pemtrexed which may be better tolerated and more effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dowell J, Taub R, Lan C, Xie Y, Dunphy F, Blake V, Kindler H: A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):7578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
  • Standard chemotherapy for MM, pemetrexed + cisplatin, yields a response rate of 41%, progression-free survival (PFS) of 5.7 months (mo) and median overall survival (OS) of 12.1 mo.
  • METHODS: Eligible pts have unresectable, histologically-confirmed MM, no prior chemotherapy, and PS 0-1.
  • Pt characteristics: male 88%; median age 66 (range 24-81); histology: epithelial 62%, sarcomatoid 15%, biphasic 20%, unknown 3%; site of origin: pleural 85%, peritoneal 12%, tunica vaginalis 3%; PS 0 32%, PS 1 68%; thrombocytosis (>400) 32%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mehran R, Gil J, Rice D, Swisher S, Lee JJ, Lippman S, Pisters K, Blumenschein G, Hong WK, Tsao AS: Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):7580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma.
  • : 7580 Background: The optimal multi-modality treatment for resectable malignant pleural mesothelioma (MPM) remains unknown.
  • METHODS: Untreated MPM patients underwent extended surgical staging (ESS) with multiple biopsies to account for tumor heterogeneity, lymph node status and to rule out sarcomatoid features.
  • If either a radiographic or molecular response (de-phosphorylation of Src Tyr419 in tumor) is achieved, an additional 2 years of dasatinib maintenance after adjuvant radiotherapy and systemic chemotherapy is given.
  • Secondary endpoints included response, survival, safety/toxicity, and biomarker modulation in tumor/serum/platelets/pleural effusion.
  • The total planned sample size is 24 to detect a 50% reduction in positive p-Src Tyr419 expression with 80% power, one-sided 10% type I error rate, and 10% inevaluable rate.
  • Two patients are still receiving neoadjuvant dasatinib; and 2 patients were deemed to not be surgical candidates due to a rapid decline in PS and one was found to have bilateral mesothelioma.
  • Post-surgical grade 3 toxicity included anemia, electrolyte abnormalities, arrhythmia, HTN, and pleural effusion; one grade 4 episode of hyperglycemia was seen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963377.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Melloni G, Puglisi A, Ferraroli GM, Carretta A, Ceresoli G, Calori G, Zannini P: [Treatment of malignant pleural mesothelioma]. Minerva Chir; 2001 Jun;56(3):243-50
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant pleural mesothelioma].
  • BACKGROUND: In this study all patients observed between January 1993 and October 1997 with malignant pleural mesothelioma (MPM) have been analyzed in order to describe the impact of treatment modality on survival.
  • In 34 cases the histotype was epithelial, in 4 sarcomatoid, in 4 mixed, in 3 desmoplastic, and in 11 not specified.
  • Four treatment modalities were identified:.
  • 2) Chemotherapy = 19 patients;.
  • 3) Surgery+Chemo-therapy = 8 patients;.
  • 2) Chemotherapy = 7.5 months;.
  • 3) Surgery+Chemotherapy = 12 months;.
  • Using univariate analysis, 8 prognostic factors were studied (age, sex, asbestos exposure, side, histotype, performance status, stage, treatment).
  • Among these, only the stage and the performance status had shown a prognostic value on survival (p<0.05), while the treatment modality had not significantly influenced the prognosis.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11423790.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 32
  •  go-up   go-down


21. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E: Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer; 2001 Nov;34(2):279-87
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
  • One-hundred and twenty-one cases of malignant pleural mesothelioma (MPM) seen between 1986 and 1999 at the authors' Institution were reviewed.
  • Ninety-one patients received a treatment (38 palliative pleurectomy and no further therapy, 16 palliative pleurectomy followed by chemotherapy, 37 chemotherapy alone), while 30 were referred to supportive care only.
  • Univariate analysis of subgroups showed that poor performance status (PS), non-epithelial histotype, Butchart stage>I and International Mesothelioma Interest Group (IMIG) stage>I were individually associated with lower survival.
  • Patients receiving any therapy survived longer than patients treated with supportive care only (P=0.0004).
  • Treatment modality had an independent prognostic value (P=0.00005), with a survival advantage for patients receiving surgery and adjuvant chemotherapy.
  • Multivariate analysis confirmed the independent prognostic value of PS (P=0.001; HR=2.48) and treatment modality (P=0.003; HR=1.38).
  • The prognostic role of PS (P=0.02) and treatment modality (P=0.01) was confirmed in the subset of patients with epithelial histology.
  • On the contrary, therapy had no impact on survival in patients with sarcomatoid MPM (P=0.74).
  • Despite the predicted bias of a retrospective non-randomized evaluation of treatment-related factors, patients with good PS and epithelial histology seemed to have a survival benefit from surgery or multimodality therapy, as opposite to patients with poor PS or non-epithelial histotype.
  • However, these results must be confirmed in a larger prospective trial with uniform treatment.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679187.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


22. Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA: Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg; 2010 Mar;89(3):907-11
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
  • BACKGROUND: Debate remains about the relative prognostic importance of the histologic subtype of malignant pleural mesothelioma.
  • METHODS: From a prospective database, the details of 312 malignant pleural mesothelioma surgical patients were reviewed.
  • A comparison was made of the survival from the three major cell types.
  • Final histologic subtype was epithelioid in 218 patients, biphasic in 66 patients, and sarcomatoid in 28 patients.
  • The median survival was 15.3 months in the epithelioid group, 10.1 months in the biphasic group, and 5.0 months in the sarcomatoid group.
  • On univariate analysis in the epithelioid group, age (p = 0.005), International Mesothelioma Interest Group stage (p = 0.001), radicality of the procedure (p = 0.001), leukocytosis (p = 0.016), and preoperative or postoperative chemotherapy (p = 0.012) were significant prognostic factors influencing postoperative survival.
  • In sarcomatoid patients, International Mesothelioma Interest Group stage and radicality of the surgical procedure were significant prognostic variables (p = 0.012 and p = 0.015, respectively).
  • Multivariate analysis in the epithelioid group identified International Mesothelioma Interest Group stage (p = 0.001), radicality of the procedure (p = 0.008), and preoperative or postoperative chemotherapy (p = 0.007) as significant prognostic factors, whereas in the sarcomatoid group, only the International Mesothelioma Interest Group stage (p = 0.012) was significant and the radicality of surgery had no effect.
  • CONCLUSIONS: The extremely poor prognosis of sarcomatoid malignant pleural mesothelioma is independent of the extent of surgery unlike other cell types.
  • Patients with sarcomatoid histology should therefore be considered separately in trials evaluating radical procedures and adjuvant treatment.
  • The treatment of biphasic pleural mesothelioma remains debatable.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20172152.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Mutafoğlu-Uysal K, Kargi A, Sarialioğlu F, Olgun N, Kovanlikaya A: Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen. Turk J Pediatr; 2002 Jul-Sep;44(3):244-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.
  • Malignant mesothelioma is a very rare tumor in childhood.
  • Presently, treatment of this disease continues to be frustrating and prognosis remains poor.
  • We here report a pediatric case of malignant pleural mesothelioma who gave a complete response to ICE-VAC chemotherapy regimen and achieved a long-term survival.
  • An eight-year-old girl underwent exploratory thoracotomy and decortication because of a unilateral loculated and multicystic pleural effusion.
  • Histopathological diagnosis was sarcomatoid pleural malignant mesothelioma.
  • After decortication, chemotherapy with ICE (ifosfamide, carboplatin, etoposide) - VAC (vincristine, adriamycin, cyclophosphamide) combination was started.
  • Six courses of chemotherapy resulted in complete clinical and radiological tumor response.
  • She did not receive any further therapy and remains disease-free three years after the first remission.
  • ICE-VAC chemotherapy combination resulted in a complete tumor response and a long-term disease-free survival for the presented case.
  • The efficacy of this chemotherapy regimen in malignant mesothelioma needs to be documented in future trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Etoposide / therapeutic use. Ifosfamide / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Child. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12405438.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3; VAC protocol
  •  go-up   go-down


24. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol; 2000 Dec 01;18(23):3912-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
  • PURPOSE: To evaluate the response rate and impact on quality of life of vinorelbine given as cycles of 30 mg/m(2) weekly for 6 weeks to patients with malignant pleural mesothelioma.
  • PATIENTS AND METHODS: Twenty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and three female patients; median age, 58 years [range, 29 to 77 years]).
  • Seventeen patients had epithelioid tumors, two had sarcomatoid tumors, and 10 had biphasic tumors.
  • The International Mesothelioma Interest Group staging system was used: one patient had stage Ib disease, 10 had stage II disease, eight had stage III disease, and 10 had stage IV disease.
  • The new guidelines to evaluate the response to treatment in solid tumors were used.
  • Responses were measured by spiral computed tomography scan.
  • There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%).
  • Quality-of-life analyses showed a benefit for vinorelbine therapy.
  • CONCLUSION: Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma.
  • The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11099320.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


25. Cukić V, Ustamujić A, Lovre V, Zutić H, Genjac S, Masić-Zecević M: Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis "Podhrastovi" in ten-year period (from 1998 to 2007). Bosn J Basic Med Sci; 2008 Nov;8(4):361-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis "Podhrastovi" in ten-year period (from 1998 to 2007).
  • Malignant pleural mesothelioma (MPM) is the most common primary malign tumour of pleura.
  • The patients were analysed according to age, sex, histopathologic type of the tumour, cantonal distribution in Federation of Bosnia and Herzegovina and regimen of treatment.
  • Histopathology types of hospitalised cases of MPM: epitheloid form (8- 28,57%); sarcomatoid form (2- 7,14 %); other forms (18-64,29%).
  • The therapy applied: chemotherapy (11-39,29%); radiotherapy (3-10,71%); chemotherapy + radiotherapy (4-14,29%); symptomatic therapy (10-35,71 %).


26. Mineo TC, Ambrogi V, Cufari ME, Pompeo E: May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg; 2010 Sep;38(3):245-52
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
  • OBJECTIVES: The expression of cyclooxygenase-2 (COX-2) and cell-cycle proteins (p21 and p27) proves useful in predicting prognosis and orientating therapy in many malignant tumours.
  • Malignant pleural mesothelioma is an uncommon and lethal cancer for which there are limited treatment options.
  • In this study, we evaluated the impact on prognosis and the influence on therapeutic strategy of immunohistochemical expression of COX-2, p21 and p27 in specimens from patients treated for malignant pleural mesothelioma.
  • METHODS: We retrospectively reviewed immunohistochemical expression of COX-2, p21 and p27 dichotomised into high and low expression from specimens of 77 consecutive patients undergoing biopsy-plus-pleurodesis (n=6), pleurectomy-decortication (n=44) or extrapleural pneumonectomy (n=27) operations for malignant pleural mesothelioma between 1987 and 2007.
  • Histology was of epithelioid (n=50), biphasic (n=17) and sarcomatoid (n=10) subtypes.
  • Therapies used were sole adjuvant radiotherapy (n=17), adjuvant radio-chemotherapy (n=56) and neo-adjuvant chemotherapy plus adjuvant radiotherapy (n=4).
  • From 2005 on, preoperative maximal standard uptake value (SUV(MAX)) was also measured by fluorodeoxyglucose positron-emission-tomography.
  • Survival was negatively influenced by histology (epithelioid vs biphasic vs sarcomatoid) (p=0.009), positive macroscopic resection margins (p=0.016), metastatic mediastinal lymph nodes (p=0.016), high COX-2 (p=0.0001) expression, low p21 (p=0.0001) expression and low p27 (p=0.001) expression.
  • Conversely, neither the type of surgery (biopsy-plus-pleurodesis vs pleurectomy-decortication vs extrapleural pneumonectomy), nor preoperative SUV(MAX) (> or = 6.0 vs <6.0), or combined therapies (sole radiotherapy vs adjuvant radio-chemotherapy vs neo-adjuvant chemotherapy plus adjuvant radiotherapy) reached a significant level of difference.
  • Cox regression analysis showed that only immunohistochemical triple combination of high COX-2 and low p21 and p27 expression influenced survival (p=0.0001, hazard ratio 4.7, 95% confidence intervals 3-11) regardless of type of treatment.
  • CONCLUSIONS: At Cox regression analysis, a combination of high COX-2 and low p21 and p27 expression resulted in the only negative prognosticator of malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclooxygenase 2 / metabolism. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Pneumonectomy. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Sep;38(3):252-3 [20634085.001]
  • (PMID = 20338775.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Neumann V, Rütten A, Scharmach M, Müller KM, Fischer M: Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register. Int Arch Occup Environ Health; 2004 Apr;77(3):191-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register.
  • Between 1987 and 2000, the German mesothelioma register recorded a total of 4,455 patients with malignant mesotheliomas.
  • Survival times for 498 (11.2%) patients were available; 155 patients (study group, 3.5% of the total group) survived for more than 2 years and 343 patients (control group, 7.7% of the total group) survived for fewer than 24 months.
  • The proportion of pleural mesotheliomas was more than 90% in both groups, with peritoneal cases comprising 6.5% in the study group and 3.2% in the control group.
  • Only 7% of tumours were of the sarcomatoid subtype.
  • In the majority of the total group pleural effusions were the first symptoms.
  • Therapeutic data were available in fewer than 40% of all cases.
  • Surgical interventions were performed, partly in combination with radiation and chemotherapy and as alternative treatments.
  • Significant deviations in survival time dependent on therapy applied could not be proved.
  • [MeSH-major] Asbestos / toxicity. Mesothelioma / mortality. Pericardium / pathology. Peritoneal Neoplasms / mortality. Pleural Neoplasms / mortality. Survival Analysis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1241-5 [10450672.001]
  • [Cites] Hum Gene Ther. 1998 May 1;9(7):1083-92 [9607419.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Pneumologie. 1991 Apr;45(4):153-8 [1876592.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Am J Gastroenterol. 1981 Apr;75(4):311-3 [7258177.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):62-9 [11836670.001]
  • [Cites] Chirurg. 2000 Aug;71(8):887-93 [11013807.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Nucl Med. 2000 Aug;41(8):1443-4 [10945542.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] Oncology (Williston Park). 2002 Jul;16(7):907-13; discussion 916-7, 919-20, 925 [12164558.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1650-6 [7417959.001]
  • [Cites] Chest. 1988 Jan;93(1):159-62 [3335148.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2000 Apr;12(2):119-29 [10807434.001]
  • [Cites] Pathologe. 1999 May;20(3):169-76 [10412176.001]
  • [Cites] Lung Cancer. 2000 Mar;27(3):205-8 [10699694.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Pathologe. 1980 Nov;2(1):8-18 [7465548.001]
  • [Cites] Chest. 1998 Jan;113(1 Suppl):66S-73S [9438693.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):246-51 [9496827.001]
  • [Cites] Scand J Work Environ Health. 2000 Apr;26(2):112-7 [10817376.001]
  • [Cites] Cancer. 1982 Jun 1;49(11):2431-5 [7074556.001]
  • [Cites] Anat Pathol. 1997;2:147-63 [9575374.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1673-9 [12738720.001]
  • [Cites] Cancer Gene Ther. 2000 Nov;7(11):1421-5 [11129284.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):466-71 [9012475.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 [11563601.001]
  • [Cites] J Occup Med. 1992 Jul;34(7):718-21 [1494965.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Feb;128(2):65-72 [11862475.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):97-101 [11836674.001]
  • [Cites] Curr Oncol Rep. 2002 Jul;4(4):305-13 [12044240.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1540-51 [3742473.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Occup Environ Med. 1997 Jun;54(6):403-9 [9245946.001]
  • [Cites] Arch Pathol Lab Med. 1982 Oct 8;106(11):544-96 [6897166.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):77-81 [11836672.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] World J Surg. 2001 Feb;25(2):210-7 [11338024.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] J Pathol. 2002 Jun;197(2):218-23 [12015746.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Am J Ind Med. 2000 Feb;37(2):159-68 [10615096.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7):919-26; discussion 926, 931-2 [10442339.001]
  • [Cites] Pneumologie. 1997 Apr;51(4):335-44 [9221379.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 14991330.001).
  • [ISSN] 0340-0131
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


28. Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN: Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer; 2010 Jan;11(1):30-5
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide.
  • Treatment options are limited, and response to chemotherapy is poor.
  • The aim of this phase II study was to evaluate the activity of the carboplatin/pemetrexed combination as first-line chemotherapy in patients with unresectable MPM.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with histologically confirmed MPM and an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled.
  • Treatment consisted of pemetrexed 500 mg/m2 and carboplatin area under the concentration-time curve of 5 mg/mL/min, both administered on day 1 of a 21-day cycle.
  • The treatment continued until 6 cycles were completed or until unacceptable toxicity or disease progression were observed.
  • The median overall survival (OS) was estimated at 14 months (95% CI, 11.8-16.2 months), and the median time to progression was 7 months (95% CI, 5.8-8.2 months).
  • The difference in median OS between the epithelial histologic subtype (16 months) and the sarcomatoid subtype (11 months) was statistically significant.
  • CONCLUSION: This study confirmed the activity of the carboplatin/ pemetrexed combination in the first-line treatment of patients with MPM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Disease Progression. Female. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Pemetrexed. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085865.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


29. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA: Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg; 2008 Oct;34(4):886-91
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
  • OBJECTIVE: To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP).
  • RESULTS: The two groups were similar for age and gender distribution but epithelioid type was more predominant in group R: 78% compared to 55% epithelioid in group NR.
  • More patients in group R received adjuvant chemotherapy (65% vs 28%, p=0.000) and radiotherapy (65% vs 26%, p=0.000).
  • Median survival for all cell types was significantly higher in group R (15.3 months vs 7.1 months, p<0.000).
  • For epithelioid cell type there was still a significant median survival advantage in group R (25.4 months vs 10.2 months, p<0.000), but there was no difference for sarcomatoid (9.3 months vs 3.2 months, p=0.16) or biphasic cell types (9.4 months vs 7 months, p=0.38).
  • CONCLUSION: If a patient with epithelioid MPM is fit enough to tolerate a thoracotomy then macroscopic clearance of the tumour is the preferred option as part of a multimodality regime including chemotherapy.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / contraindications. Radiotherapy, Adjuvant. Survival Analysis. Thoracotomy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656373.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Kindler HL: Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol; 2008 Jun;9(2-3):171-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatments for mesothelioma: standard and novel.
  • OPINION STATEMENT: Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery.
  • For many years, chemotherapy had a minimal impact on the natural history of this cancer, engendering considerable nihilism.
  • Countless drugs were evaluated, most of which achieved response rates below 20% and median survival of <1 year.
  • Several factors have hampered the evaluation of systemic regimens in patients with mesothelioma.
  • Since all of the staging systems for mesothelioma are surgically based, it is almost impossible to accurately determine the stage of a patient who has not been resected.
  • The disease itself is heterogenous, with many different prognostic factors, most notably three pathologic subtypes--epithelial, sarcomatoid, and biphasic--that have different natural histories, and varying responses to treatment.
  • Finally, response assessment is problematic, since pleural-based lesions are difficult to measure accurately and reproducibly.
  • Despite these limitations, in recent years, there has been a surge of optimism regarding systemic treatment of this disease.
  • Several cytotoxic agents have been shown to generate reproducible responses, improve quality of life, or prolong survival in mesothelioma.
  • Drugs with single-agent activity include pemetrexed, raltitrexed, vinorelbine, and vinflunine.
  • There are also several unresolved questions about the duration and timing of treatment with pemetrexed that are the subject of planned clinical trials.
  • Other active drugs or drug combinations may be more appropriate for specific individuals, and further research is still needed to improve upon these results.
  • Now that effective agents have been developed for initial treatment, several classical cytotoxic drugs and many novel agents are being evaluated in the second-line setting.
  • These include drugs targeted against the epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, src kinase, histone deacetylase, the proteasome, and mesothelin.
  • Given the progress made in recent years, there is reason to believe that more effective treatments will continue to be developed.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Comorbidity. Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / therapeutic use. Humans. Medical Oncology / methods. Pemetrexed. Prognosis. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1556-61 [12697881.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6434-7 [12438230.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):1981-5 [6627213.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):527-35 [3351560.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):956-60 [1616870.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):25-30 [10458214.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2300-4 [15788680.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1962-72 [17620427.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):423-8 [15893012.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):75-82 [16005104.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):521-2 [16052537.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii [16325127.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1137-45, viii [16325128.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):270-5 [16317014.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1443-8 [16549838.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):93-9 [17146783.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] J Thorac Oncol. 2006 Jan;1(1):25-30 [17409823.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):317-20 [17409804.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2406-13 [17557954.001]
  • [Cites] Oncologist. 2007 Jul;12(7):808-15 [17673612.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5942-51 [17908991.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4751-6 [17947722.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7166-71 [18056197.001]
  • [Cites] Cancer Immun. 2007;7:20 [18088084.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):46-53 [17945478.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58 [17522864.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1465-71 [18349397.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1772-9 [18224661.001]
  • [Cites] Lung Cancer. 2008 May;60(2):259-63 [18006112.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1685-94 [18486741.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):51-6 [18542071.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):44-50 [18542078.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):94-7 [18486273.001]
  • [Cites] J Clin Oncol. 2012 Jul 10;30(20):2509-15 [22665541.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):15-8 [15849999.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1985-91 [10570422.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):497-9 [11398882.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):289-95 [11679188.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):70-6 [11836671.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 18770046.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2782121
  •  go-up   go-down


31. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


32. Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, Norton A, Ashley S, Smith IE: The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol; 2004 Sep;15(9):1406-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
  • BACKGROUND: With the rising incidence of malignant mesothelioma (MM), it is important to optimise treatment to control symptoms, maintain quality of life and, if possible, prolong life.
  • We have analysed prospectively collected data to evaluate a frequently used palliative chemotherapy regimen.
  • PATIENTS AND METHODS: Between October 1986 and May 2002 all patients with inoperable pleural mesothelioma were considered for treatment with MVP (mitomycin C 8 mg/m2 every 6 weeks, vinblastine 6 mg/m2 every 3 weeks and cisplatin 50 mg/m2 every 3 weeks) chemotherapy.
  • Symptoms were assessed by physician assessment at baseline and after each cycle of chemotherapy.
  • RESULTS: One hundred and fifty patients were treated with MVP for mesothelioma.
  • Poor prognostic factors in univariate analysis included poor PS, weight loss, mixed or sarcomatoid histology, low haemoglobin and high white blood cell count.
  • CONCLUSIONS: Palliation of symptoms in MM is achievable with current cisplatin-based treatments.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15319247.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jänne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH: Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1366-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
  • PURPOSE: Extrapleural pneumonectomy (EPP) is an effective treatment of malignant pleural mesothelioma.
  • We compared the outcomes after moderate-dose hemithoracic radiotherapy (MDRT) and high-dose hemithoracic RT (HDRT) after EPP for malignant pleural mesothelioma.
  • Between 1994 and 2002, MDRT, including 30 Gy to the hemithorax, 40 Gy to the mediastinum, and boosts to positive margins or nodes to 54 Gy, was given, generally with concurrent chemotherapy.
  • In 2003, HDRT to 54 Gy with a matched photon/electron technique was given, with sequential chemotherapy.
  • The histologic type was epithelial in 25 patients (64%) and mixed or sarcomatoid in 14 patients (36%).
  • The median time to distant failure (DF) and local failure (LF) was 20 months (95% confidence interval, 14-26) and 26 months (95% confidence interval, 16-36), respectively.
  • On univariate and multivariate analyses, only a mixed histologic type was predictive of inferior DF (p <0.006) and overall survival (p <0.004).
  • [MeSH-major] Mesothelioma / radiotherapy. Mesothelioma / surgery. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Combined Modality Therapy / methods. Confidence Intervals. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674974.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


34. Carbone M, Rizzo P, Powers A, Bocchetta M, Fresco R, Krausz T: Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res; 2002 Nov-Dec;22(6B):3443-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
  • BACKGROUND: Only recently pleural synovial sarcomas (SS) have been definitively identified because of the presence of a characteristic X;18 translocation.
  • SS are sarcomatoid or biphasic malignancies morphologically almost indistinguishable from sarcomatoid or biphasic malignant mesotheliomas (MM).
  • PATIENT AND METHODS: We demonstrated a primary pleural biphasic SS in a patient referred to us has having a biphasic MM.
  • Detection of the t(X:18) translocation using RT-PCR, Southern blot, and DNA sequencing definitively confirmed the diagnosis of SS.
  • CONCLUSION: The differential between pleural SS and MM requires a high degree of suspicion and molecular analyses because morphology (histology, immunohistochemistry and electron microscopy) is insufficient to definitively distinguish between these two malignancies.
  • This differential is critical because patients with pleural SS can be susceptible to chemotherapy, and accordingly are treated, while patients with sarcomatoid MM are resistant to chemotherapy and accordingly are not treated.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552937.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA-92657
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement